Pituitary Dwarf Treatment Global Market Report 2024 - By Report, Size, Share, Demand, Forecast TO 2033

The pituitary dwarf treatment market size has grown rapidly in recent years. It will grow from $4.76 billion in 2023 to $5.52 billion in 2024 at a compound annual growth rate (CAGR) of 15.9%. The growth in the historic period can be attributed to increasing demand for pituitary dwarf treatment drugs, growing prevalence of pituitary dwarfism, awareness of pituitary dwarfism.

The pituitary dwarf treatment market size is expected to see rapid growth in the next few years. It will grow to $9.4 billion in 2028 at a compound annual growth rate (CAGR) of 14.2%. The growth in the forecast period can be attributed to rising geriatric population, rising healthcare spending, growth hormone treatment, growing demand for prescription treatments for pituitary dwarfism. Major trends in the forecast period include advancements in medical research, drug approvals, advancements in drug delivery systems, innovative growth hormone formulations, genetic testing.

Market Overview -
Pituitary dwarf is a medical condition in which the pituitary gland fails to produce sufficient growth hormone (GH). This deficiency leads to impaired growth and development in affected individuals, resulting in short stature or dwarfism. The pituitary dwarf treatment stimulates the growth of bones, muscles and other tissues, which can cause a noticeable increase in height and overall physical development.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=12923&type=smp

Growth Hormone Deficiency Drives Growth In The Pituitary Dwarf Treatment Market
The growing prevalence of growth hormone deficiency is expected to propel the growth of the pituitary dwarf treatment market going forward. Growth hormone deficiency (GHD) is a medical condition characterized by the pituitary gland's inadequate production or secretion of growth hormone (GH). The pituitary dwarf treatment provides hormonal therapies that increase growth and bone health, regulate metabolism and improve the quality-of-life suffering from dwarfism and growth hormone deficiency. For instance, in January 2021, according to the European Medicines Agency (EMA), a UK-based decentralized agency, an estimated 6,000 adults will be diagnosed with adult growth hormone deficiency (AGHD) each year in the US. Therefore, the growing prevalence of growth hormone deficiency is driving the growth of the pituitary dwarf treatment market.

Competitive Landscape -
Major players in the pituitary dwarf treatment market are Pfizer Inc., Merck and Co Inc., Novartis AG, Sanofi S.A., Eli Lilly and Company, Novo Nordisk A/S, H. Lundbeck A/S, Mylan N.V., Teva Pharmaceutical Industries Ltd., Ipsen Pharma S.A., Genentech Inc., Apotex Inc., Cipla Limited, Ferring Pharmaceuticals, Anhui Anke Biotechnology (Group) Co Ltd., Amneal Pharmaceuticals LLC., BioMarin Pharmaceutical Inc., Biopartners GmbH, Elekta AB, Xiamen Amoytop Biotech Co Ltd., Lifetech Labs, Alnylam Pharmaceuticals Inc., GeneScience Pharmaceuticals Co Ltd., Armata Pharmaceuticals Inc., Alkermes Plc.

Market Focus On Innovative Products Drives Growth In Pituitary Dwarf Treatment
Major companies operating in the pituitary dwarf treatment market are focusing on developing innovative products to sustain their position in the market. For instance, in April 2023, Novo Nordisk A/S, a Denmark-based pharmaceutical company, introduced Sogroya (somapacitan-beco) injections of 5 mg, 10 mg, or 15 mg approved by the Food and Drug Administration (FDA), a US-based government agency. Sogroya treats children aged 2.5 years and older with growth deficiencies due to insufficient endogenous growth hormone secretion. With this additional indication, Sogroya is now the only once-weekly growth hormone (GH) medication available for children and adults.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/pituitary-dwarf-treatment-global-market-report

Key Segments -
The pituitary dwarf treatment market covered in this report is segmented -
1) By Type: Pituitary Dwarfism Type I; Pituitary Dwarfism Type II; Pituitary Dwarfism Type III; Pituitary Dwarfism Type IV; Other Types
2) By Treatment: Surgery; Additional Therapy; Drugs; Other Treatments
3) By Route Of Administration: Parenteral; Other Routes Of Administrations
4) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model"

Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.